Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ritz

Showing results (131-140 of 297) with videos related to

Pageof 30
Sort By:
Experimental Hematology|February 1, 1996
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemiaM J Robertson, K J Cochran, C Cameron, et al.
Blood|March 7, 1998
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1J A Gollob, E A Murphy, S Mahajan, et al.
The Journal of Experimental Medicine|June 1, 1986
A lymphokine that activates the cytolytic program of both cytotoxic T lymphocyte and natural killer clonesC Milanese, R F Siliciano, R E Schmidt, et al.
Immunology|March 1, 1996
Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expressionM E Taplin, M E Frantz, C Canning, et al.
Blood|June 1, 1991
Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cellsD C Roy, J D Griffin, M Belvin, et al.
European Journal of Immunology|January 1, 1992
Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cellsD M Baume, M J Robertson, H Levine, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1988
Induction of natural killer effectors from human thymus with recombinant IL-2J M Michon, M A Caligiuri, S M Hazanow, et al.
Blood|February 15, 1995
Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrationsR J Soiffer, C Murray, J Ritz, et al.
Cancer Treatment and Research|January 1, 1988
Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complementA S Freedman, T Takvorian, L M Nadler, et al.
The Journal of Clinical Investigation|January 1, 1987
Enhancement of natural killer function through activation of the T11 E rosette receptorR E Schmidt, J M Michon, J Woronicz, et al.
Pageof 30

Showing results (131-140 of 297) with videos related to

Sort By:
Pageof 30
Experimental Hematology|February 1, 1996
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemiaM J Robertson, K J Cochran, C Cameron, et al.
Blood|March 7, 1998
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1J A Gollob, E A Murphy, S Mahajan, et al.
The Journal of Experimental Medicine|June 1, 1986
A lymphokine that activates the cytolytic program of both cytotoxic T lymphocyte and natural killer clonesC Milanese, R F Siliciano, R E Schmidt, et al.
Immunology|March 1, 1996
Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expressionM E Taplin, M E Frantz, C Canning, et al.
Blood|June 1, 1991
Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cellsD C Roy, J D Griffin, M Belvin, et al.
European Journal of Immunology|January 1, 1992
Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cellsD M Baume, M J Robertson, H Levine, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1988
Induction of natural killer effectors from human thymus with recombinant IL-2J M Michon, M A Caligiuri, S M Hazanow, et al.
Blood|February 15, 1995
Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrationsR J Soiffer, C Murray, J Ritz, et al.
Cancer Treatment and Research|January 1, 1988
Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complementA S Freedman, T Takvorian, L M Nadler, et al.
The Journal of Clinical Investigation|January 1, 1987
Enhancement of natural killer function through activation of the T11 E rosette receptorR E Schmidt, J M Michon, J Woronicz, et al.
Pageof 30